Here is a strange fact about CBG: the cannabis plant spends the entire growing season destroying it. Every cannabinoid starts as CBGA (cannabigerolic acid), the biochemical raw material from which THC, CBD, and CBC all develop. As the plant matures, enzymes convert nearly all of that CBGA into those other compounds. By harvest, a typical cannabis plant contains less than 1% CBG by weight. You have to catch it early, breed specifically for it, or accept the cost of working with young plants. That scarcity is not a marketing story. It is chemistry. And the chemistry also explains why CBG’s effect profile is distinct from CBD or THC: it reaches receptor systems that those conversion products don’t interact with as effectively. These include pathways tied to norepinephrine signaling and the anandamide system. For people looking at CBG for focus and energy, those particular mechanisms are the ones that matter.
🧪 Lab Tested | 👩💼 Woman-Owned | 🏆 Est. 2017
Research context: The mechanisms in this article are based on preclinical (cell and animal) research and limited human observational data. CBG is not an approved drug or treatment. Nothing here constitutes medical advice or a claim that CBG treats, prevents, or cures any condition. Consult a physician before making health decisions based on this content.
What CBG Is and Why It Costs More
Cannabigerol (CBG) is a non-psychoactive cannabinoid. It begins its life as CBGA, the acidic precursor that serves as the biosynthetic starting point for the entire cannabinoid family. As a cannabis plant matures, specific enzymes convert CBGA into THCA, CBDA, and CBCA (the acidic precursors to THC, CBD, and CBC respectively). By the time a plant reaches harvest, almost all of the CBG has been converted away. Most cultivated cannabis contains 1% CBG or less by dry weight.
Getting concentrated CBG into a product requires one of three approaches: harvesting early before conversion is complete, breeding strains that express high CBG by retaining more CBGA in the plant, or extracting from immature plants that haven’t yet run the full conversion process. None of these is as efficient or cost-effective as working with mature CBD-dominant hemp, which is why CBG products carry a higher price per milligram than equivalent CBD products. The markup is not a premium for novelty. It is a reflection of the additional steps required to obtain meaningful CBG concentrations.
CBG does not produce psychoactivity. It does not activate CB1 receptors with the potency that generates THC’s intoxicating effect. Its receptor profile is broader than CBD’s, with meaningful activity at adrenergic receptors and serotonin receptors in addition to the cannabinoid receptor system, and that broader profile is what makes its effect on focus and energy pharmacologically interesting.
Four Mechanisms Behind the Focus Effect
CBG interacts with at least four distinct receptor systems relevant to focus and attention. None operates in isolation, and none has been tested in a rigorous human clinical trial specifically targeting these outcomes. The pharmacology is coherent and mechanistically plausible based on preclinical evidence. The clinical confirmation is not yet there.
FAAH Inhibition
CBG inhibits FAAH (fatty acid amide hydrolase), the enzyme responsible for breaking down anandamide in the body. When FAAH is inhibited, anandamide accumulates rather than degrading quickly. Anandamide activates CB1 receptors in prefrontal cortex circuits involved in attention and executive function. This produces a modulating effect on those circuits rather than the high-intensity response from THC binding directly. The effect is sustained and gentle, not stimulant-like.
Alpha-2 Antagonism
CBG blocks alpha-2 adrenoceptors. These receptors function as a feedback brake on norepinephrine release: when alpha-2 receptors are activated by norepinephrine already in the synapse, they suppress further norepinephrine output. CBG blocking them removes that suppression. More norepinephrine accumulates in the synapse. Norepinephrine supports alertness, attention, and cognitive arousal through adrenergic pathways. This mechanism is pharmacologically distinct from anything CBD does and is one of the more notable differences between the two cannabinoids for focus applications.
5-HT1A Activation
CBG activates 5-HT1A serotonin receptors, the same receptor targeted by CBD and several classes of anxiolytic compounds. 5-HT1A activation produces anxiolytic effects at a receptor level: reduced amygdala activity, lower background stress signaling. The contribution to focus is indirect. Anxiety and distractibility compete directly for working memory resources, so reducing the anxious signal can free up cognitive capacity without stimulating the system in any conventional sense. It is not an energy boost. It is the removal of an energy drain.
CB1/CB2 Partial Agonism
CBG partially agonizes both CB1 and CB2 receptors. It binds and activates them without the full receptor response that THC produces at CB1. In prefrontal cortex regions, this partial CB1 activation may modulate glutamate and dopamine signaling in circuits relevant to working memory and sustained attention. CB2 activation contributes local anti-inflammatory effects at the neuronal level. Together, these add a fourth receptor system to the others rather than replacing any of them.
CBG vs. CBD: What Is Actually Different
CBD and CBG share two of the four mechanisms above: FAAH inhibition (raising anandamide) and 5-HT1A activation (reducing anxiety). This means they produce overlapping anxiolytic and anandamide-modulating effects. The practical difference lives in the two mechanisms they do not share.
CBG shows meaningful alpha-2 antagonism. CBD does not. CBG partially agonizes CB1. CBD modulates it as a negative allosteric modulator: it changes how the receptor responds to other activators without directly turning it on. These distinctions matter for the focus use case because they explain why many people who use CBD find it relaxing to the point of sedation at moderate and higher doses, while CBG tends to maintain a clearer, more alert profile across a wider dose range.
The two are commonly combined, which is the logic behind CBG-boosted CBD products. CBD provides stronger broad-spectrum anxiolytic coverage. CBG adds the norepinephrine contribution that CBD cannot provide. Whether the combination produces effects greater than either alone is not established in controlled trials, but the receptor coverage rationale is solid. Some users find that pairing them lets them take less of each than they would need individually to reach the same outcome.
For focus specifically: if CBD alone feels too heavy or calming for daytime use, CBG or a CBG-dominant blend is the more pharmacologically appropriate alternative. That is not a judgment about which product is better in general. It reflects where in the receptor system each one acts.
Dosing Guide: Starting Points and Timing
Dosing note: The ranges below are starting reference points drawn from preclinical research, product formulation specs, and user experience data. They are not medical prescriptions. Individual response varies by body weight, tolerance, liver metabolism, and baseline endocannabinoid tone. Start low. Assess over three to five sessions before adjusting upward.
| Level | CBG Amount | Expected Profile | Timing (Tincture) | Best Format |
| New to CBG | 5 to 10mg | Subtle clarity, mild anxiety reduction. May not feel clearly distinct from CBD at this range. A useful calibration starting point. | 30 to 60 min before work | Tincture (sublingual) |
| Established user | 15 to 25mg | Clearer cognitive calm, reduced mental friction. Most commonly reported effective range for focus applications in user experience data. | 30 to 45 min before task | Tincture or CBG-boosted cart |
| Tolerance-adjusted | 25 to 50mg | Strong anxiolytic effect. Some users at this range report the profile shifts toward relaxation rather than focused alertness. Morning or early afternoon only. | 45 to 60 min before work | Tincture |
| CBG plus CBD combo | 10 to 15mg CBG + 20 to 30mg CBD | Broader receptor coverage. CBD’s stronger broad-spectrum anxiolytic activity paired with CBG’s norepinephrine contribution. Common in CBG-boosted CBD products. | 30 to 60 min before work | CBG-boosted tincture or cart |
The general pattern in user experience: CBG sits closer to the activating end of the cannabinoid spectrum than CBD. Evening use is less common with CBG-forward products, particularly at moderate and higher doses, because the norepinephrine contribution can interfere with sleep onset. Morning and early afternoon are the better windows for focus applications.
Sublingual technique matters: Hold CBG tincture under the tongue for 60 to 90 seconds before swallowing. This routes the cannabinoid directly into sublingual capillaries and bypasses first-pass liver metabolism. Onset arrives in 15 to 30 minutes rather than 60 to 90. Swallowing immediately converts a sublingual product into an oral one with slower, more variable absorption. The technique costs nothing and makes a meaningful difference in onset consistency.
Tincture, Vape, or Gummy: Format Comparison
Tinctures: most predictable for focus work
A sublingual tincture gives the most consistent onset and duration control. Hold under the tongue, onset in 15 to 30 minutes, effect window of 4 to 6 hours. The drop-by-drop format allows small dose adjustments across sessions that pre-measured formats don’t permit. For anyone calibrating CBG for a specific use case, tinctures provide the feedback loop needed to find the right dose before committing to any particular amount.
CBG-boosted vape carts: fastest onset
Inhaled cannabinoids reach peak blood concentration within 5 to 15 minutes. The trade-off is duration: inhalation typically produces a 2 to 3 hour window rather than the 4 to 6 hours from a tincture. For a shorter, defined focus block or a situation where timing is tight, a CBG-boosted CBD cart works well. The CBG content per draw in a boosted product is lower than in a dedicated CBG tincture, so the total dose delivered varies significantly by number of draws and inhalation depth. This format favors users who want quick onset rather than precise milligram control.
Gummies and edibles: slowest onset, longest duration
Oral CBG goes through first-pass liver metabolism before reaching systemic circulation. Onset ranges from 45 to 90 minutes, peak may arrive 2 to 3 hours after consumption, and duration can extend 6 to 8 hours. For a long work block with enough lead time to plan, edibles are viable. For spontaneous use or situations that need a reliable onset window, they are the least practical format.
CBG and Drug Tests
Standard drug panels (SAMHSA-5, SAMHSA-10, and most employer urine immunoassays) screen for THC-COOH, opioid metabolites, cocaine metabolites, amphetamines, and phencyclidine. CBG is not on that list. CBG itself will not trigger a positive result on any standard panel because no standard panel tests for it.
The relevant question for CBG users is what else is in the product. A CBG isolate or broad-spectrum product with Delta-9 THC removed carries no drug test risk from the CBG itself and no residual THC to accumulate. A full-spectrum CBG product retains trace Delta-9 THC alongside the CBG, because full-spectrum extraction preserves the complete cannabinoid profile of the plant. At typical serving sizes, the trace THC in a compliant full-spectrum hemp product is low enough that accumulation to detectable levels is unlikely for most users at standard dosing frequency, but it cannot be guaranteed. Individual metabolism, testing frequency, and panel sensitivity all affect where that line sits.
For anyone subject to zero-tolerance drug testing: choose a broad-spectrum or isolate-based CBG product rather than full-spectrum. Confirm on the batch COA that Delta-9 THC is at or near non-detect. The batch COA for TribeTokes products is always available at tribetokes.com/certificates-of-analysis.
TribeTokes CBG Products
Dedicated CBG Tincture
CBG Tincture | Full Spectrum, CBD + CBGa Boosted | 1,800 MG
★★★★★ 4.85 from 13 reviews
CBG
Full Spectrum
1,800mg
60 servings
Trace THC. See COA.
1,800mg CBG with CBD and CBGa in a full-spectrum organic MCT oil base. 60 servings per bottle. Hold under the tongue 60 to 90 seconds for best onset. Full-spectrum means trace Delta-9 THC is present: not recommended for zero-tolerance drug testing without checking the batch COA first. Batch-specific lab results at tribetokes.com/certificates-of-analysis. Lemon mint flavor. Keto-friendly base.
CBG-Boosted CBD Vape Carts
CBD Full Gram Carts | CBG-Boosted | Choose from 12 Strains
★★★★★ 4.85 from 72 reviews
CBD + CBG
Full Gram
12 Strains
510 Thread
CBD vape cartridges with CBG added for combined receptor coverage. Fast onset for focus sessions where timing is tight. Sativa-leaning strains (Green Crack, Mango Haze, Hawaiian Dream) carry more activating terpene profiles alongside the CBG. Full gram. Standard 510-thread connection. Batch COA available at tribetokes.com/certificates-of-analysis.
Frequently Asked Questions
Not in the stimulant sense. CBG does not increase heart rate, cause jitteriness, or block the adenosine receptors that caffeine targets. What it may produce is the removal of friction. The alpha-2 antagonism loosens the brake on norepinephrine release in the synapse, which supports alertness through adrenergic pathways. The 5-HT1A activation reduces background anxiety that competes for cognitive bandwidth. The combined effect some users describe as “energy” is closer to calm clarity: less internal noise rather than more drive. Whether that translates for a given person depends on their baseline anxiety level, sensitivity to norepinephrine modulation, and the dose.
No. CBG is non-psychoactive. At CB1 receptors, it functions as a partial agonist without the full receptor activation that produces THC’s intoxicating effects. No euphoria, no altered perception, no impaired coordination. Some users notice a subtle mood lift or sense of mental clarity, which is pharmacologically distinct from any THC-associated high.
Both inhibit FAAH and activate 5-HT1A. They share overlapping anxiolytic activity as a result. The meaningful difference for focus is that CBG also antagonizes alpha-2 adrenoceptors (which increases norepinephrine availability) and partially agonizes CB1 in prefrontal circuits. CBD does neither of those. At moderate to higher doses, CBD tends toward sedation. CBG tends to maintain a clearer profile across the dose range. For daytime cognitive use, CBG or a CBG-dominant blend is the more appropriate pharmacological choice for most users.
A practical starting point is 10 to 15mg taken sublingually 30 to 45 minutes before focused work. Most user experience data places the effective range for focus use between 10 and 25mg. Above 25 to 30mg, some users report the profile shifts toward relaxation rather than focused alertness. Start low, hold under the tongue for 60 to 90 seconds, and assess over three to five sessions before adjusting. Individual response varies considerably.
CBG itself is not screened for on any standard drug panel, so CBG on its own carries no drug test risk. The variable is the other cannabinoids in the product. Full-spectrum CBG products contain trace Delta-9 THC; at standard doses and typical testing frequency, accumulation to detectable levels is unlikely for most users but cannot be guaranteed. For zero-tolerance drug testing environments, use a broad-spectrum or isolate-based CBG product rather than full-spectrum, and confirm Delta-9 levels on the batch COA before use.
They work through different mechanisms and suit different people. Caffeine blocks adenosine receptors, which suppresses the signal that makes you feel tired. The result is alertness plus, for many people, anxiety and jitteriness as side effects. CBG works through norepinephrine and anandamide pathways to support calm attention rather than push through fatigue. Some users combine the two: caffeine for the initial wake signal, CBG to reduce the anxious edge caffeine introduces. Neither is categorically better. The right choice depends on what is actually limiting focus for a given person.
For tinctures, take 30 to 45 minutes before the start of a focus session. For vape formats, onset is faster at 5 to 15 minutes, so timing can be closer to task start. Morning and early afternoon are the better windows for focus-oriented CBG use. Later doses, particularly above 20mg, can interfere with sleep onset in people sensitive to adrenergic stimulation from the alpha-2 antagonism. Evening use makes more sense with CBD-dominant blends where CBG content is lower.
Most users describe the experience as subtle. Not dramatically different from a baseline, but slightly easier to settle into a task. The common thread in user descriptions: reduced mental static, less anxious chatter, a sense that attention lands where it is pointed without as much resistance. No euphoria, no body heaviness, nothing that would impair driving or other tasks. People who find CBD calming to the point of drowsiness often find CBG noticeably clearer in comparison. People who expect a stimulant experience are typically underwhelmed. It is not that kind of compound.
1,800mg CBG. Full Spectrum. Third-Party Tested on Every Batch.
Organic MCT oil base. Lemon mint. 60 servings. Woman-owned since 2017.